Arthritis Care & Research最新文献

{"title":"Reply.","authors":"Selene Rubino, Grant W Cannon, Brian C Sauer, Tawnie J Braaten","doi":"10.1002/acr.80154","DOIUrl":"https://doi.org/10.1002/acr.80154","url":null,"abstract":"","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148890857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing the 2025 ACR SLE Guidelines in Pakistan: Bridging the Gap Between Evidence and Access.","authors":"Saim Jan","doi":"10.1002/acr.80150","DOIUrl":"https://doi.org/10.1002/acr.80150","url":null,"abstract":"","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148890930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Within-day activity patterns in knee osteoarthritis: frailty signal or treatment marker? Comment on the article by Liles et al.","authors":"Ruoyao Cheng, Caihua He, Ying Liu","doi":"10.1002/acr.80041","DOIUrl":"10.1002/acr.80041","url":null,"abstract":"","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":"1304"},"PeriodicalIF":4.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13511304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subcutaneous Versus Intravenous Tocilizumab in Aortitis Associated With Giant Cell Arteritis: Multicenter Study of 196 Patients.","authors":"Carmen Secada-Gómez, Javier Loricera, Adrián Martín-Gutiérrez, Javier Narváez, Vicente Aldasoro, Olga Maiz, Paloma Vela, Susana Romero-Yuste, Eugenio de Miguel, Eva Galíndez-Agirregoikoa, Jesús C Fernandez-López, Iván Ferraz-Amaro, Julio Sanchez-Martín, Patricia Moya-Alvarado, Cristina Campos, Santos Castañeda, Ricardo Blanco","doi":"10.1002/acr.80006","DOIUrl":"10.1002/acr.80006","url":null,"abstract":"<p><strong>Objective: </strong>Aortitis associated with giant cell arteritis (GCA) is a severe manifestation, potentially leading to aneurysms and aortic dissection. Tocilizumab (TCZ) has demonstrated efficacy in the treatment of GCA, both intravenously or subcutaneously administered. However, pivotal studies did not specifically evaluate aortic involvement, and no comparison of intravenous (IV) versus subcutaneous (SC) TCZ has been performed in patients with GCA-related aortitis. The objective of this study was to compare the effectiveness of TCZ according to the administration route in patients with GCA-associated aortitis under clinical practice conditions.</p><p><strong>Methods: </strong>This was a multicenter observational study including 196 patients diagnosed with GCA-associated aortitis by imaging and treated with TCZ. Patients were grouped by administration route: IV or SC. GCA was diagnosed following the 1990 American College of Rheumatology criteria, temporal artery biopsy, and/or vascular imaging. Aortitis was identified using ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography scan. Main outcomes included EULAR remission, clinical and imaging remission, absence of systemic inflammation, and glucocorticoid-sparing effect.</p><p><strong>Results: </strong>Of 196 patients (148 women; mean age 69.8 ± SD 9.4 years), 110 received IV TCZ and 86 SC TCZ. Baseline clinical characteristics and markers of inflammation were comparable between groups. The glucocorticoid-sparing effect was similar. At 24-month follow-up, EULAR-defined remission was significantly more frequent in the SC group (83.3% vs 80.6%; P < 0.05). However, rates of imaging remission and absence of systemic inflammation were comparable between treatment arms.</p><p><strong>Conclusions: </strong>In this real-world cohort of GCA-associated aortitis, SC TCZ showed slightly greater effectiveness than IV TCZ in achieving EULAR-defined remission, whereas no significant differences were observed between both routes regarding imaging remission.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":"1256-1264"},"PeriodicalIF":4.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13511453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145965053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply.","authors":"Daniel K White, Sydney C Liles","doi":"10.1002/acr.80042","DOIUrl":"10.1002/acr.80042","url":null,"abstract":"","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":"1305"},"PeriodicalIF":4.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13511294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147497636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Implementing a Dashboard With or Without a Best Practice Alert on HLA-B*58:01 Testing Rates Among Allopurinol Users at VA Medical Centers.","authors":"Abimbola Fadairo-Azinge, Gabriela Schmajuk, Sristi Sharma, Colleen P Flanagan, Sara Faghihi-Kashani, Ning Zhang, Mary A Whooley","doi":"10.1002/acr.80016","DOIUrl":"10.1002/acr.80016","url":null,"abstract":"<p><strong>Objective: </strong>The American College of Rheumatology recommends HLA-B*58:01 allele testing before the initiation of allopurinol, specifically among Asian and African American/Black patients, due to their increased risk for severe hypersensitivity reactions. However, testing rates remain low at many health care facilities. This study aimed to determine whether the introduction of a clinician-facing dashboard, with or without a best practice alert (BPA), would increase HLA-B*58:01 testing rates among eligible patients at two VA medical centers.</p><p><strong>Methods: </strong>In October 2022, we launched a clinician-facing dashboard that displayed HLA-B*58:01 testing results for all patients prescribed allopurinol at two VA medical centers. In January 2023, we added a synchronous BPA that appeared at one of the two medical centers whenever a provider entered a prescription for allopurinol. The BPA was presented as blue text on the medication order entry form and stated \"HLA-B*58:01 genotyping recommended before rx for Asian or African American.\" Using data from the electronic health record, we compared the change in proportion of patients receiving allopurinol prescriptions who had HLA-B*58:01 genotype testing done after implementation of the dashboard (±BPA) at the two VA medical centers.</p><p><strong>Results: </strong>From October 2022 through December 2023, the number of Asian or African American/Black patients who filled one or more prescriptions for allopurinol was 262 at the BPA + dashboard site and 330 at the dashboard only site. The percentage of Asian or African American/Black patients who had HLA-B*58:01 testing before or during the month allopurinol was prescribed increased from 8.8% in October 2022 to 35.5% in December 2023 at the dashboard + BPA site and from 2.1% to 4.5% at the dashboard only site (P < 0.0001 for difference in difference). The cumulative percentage of prescribers whose patient(s) completed HLA-B*58:01 testing increased from 11.7% to 46.8% at the dashboard + BPA site and from 6.9% to 10.8% at the dashboard only site (P < 0.0001 for difference in difference).</p><p><strong>Conclusion: </strong>Implementing a dashboard plus simple text BPA was associated with a greater increase in the proportion of patients who completed guideline-recommend HLA-B*58:01 testing compared to implementing a dashboard alone.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":"1265-1269"},"PeriodicalIF":4.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13511291/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146148876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Major US Formulary Change Triggers, but Does Not Sustain, Increases in Biosimilar Adalimumab Prescribing.","authors":"Eric T Roberts, Gabriela Schmajuk, Mackenzie Clark, Diana Ung, Jinoos Yazdany","doi":"10.1002/acr.80024","DOIUrl":"10.1002/acr.80024","url":null,"abstract":"<p><strong>Objective: </strong>CVS Caremark changed their national commercial formularies in 2024 to prefer adalimumab-adaz over originator. We assessed the formulary change's effect on biosimilar adalimumab prescribing in US community rheumatology practices.</p><p><strong>Methods: </strong>Data come from Rheumatology Informatics System for Effectiveness, a registry of electronic health record data from participating community rheumatology practices nationwide. We used interrupted time series to analyze the effect of the CVS formulary change on the proportion of patients prescribed adalimumab-adaz or other adalimumab biosimilars each month between January 2023 and September 2024 stratified by payor and among new users.</p><p><strong>Results: </strong>We included 22,079 patients. Among those commercially insured, prescriptions for adalimumab-adaz went from nearly 0% to more than 25% following the CVS formulary change. In the next month, prescriptions for adalimumab-adaz dropped 12.3%. Prescriptions for other biosimilars increased slowly and linearly over the study period. Among patients with Medicare, we observed a similarly timed, but much smaller, increase in prescribing for both adalimumab-adaz and other biosimilar molecules without a large subsequent decrease. Among new users, prescriptions for adalimumab-adaz increased from 0% to 24% but was followed by a nearly 14% decrease in prescriptions in the first month after the formulary change. Other biosimilar prescriptions increased 0.6% per month throughout the period.</p><p><strong>Conclusions: </strong>Although biosimilar adalimumab prescriptions rose sharply after a major national formulary change, the increase was not sustained. These findings highlight that persistent barriers, including the nocebo effect and the administrative burden of switching, may continue to limit biosimilar adoption and contribute to the loss of substantial cost savings in the US market.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":"1287-1297"},"PeriodicalIF":4.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13511434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146199985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reproductive Health Counseling in Rheumatology: Gaps, Barriers, and Patient Impact.","authors":"Daniele Marcy, Kristin Sturm, Tara Skorupa, Caroline Maretz, Guiset Carvajal Bedoya, Aaron Lazorwitz, Ju Young Kwag, M Kristen Demoruelle, JoAnn Zell","doi":"10.1002/acr.80014","DOIUrl":"10.1002/acr.80014","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the frequency and factors associated with reproductive health counseling. We also aimed to assess barriers to counseling and introduce clinical interventions that could reduce these barriers.</p><p><strong>Methods: </strong>A total of 101 female patients of childbearing potential who were not planning pregnancy completed a survey that included questions to determine whether they had previously received reproductive health counseling by a rheumatologist. This represented 18% of women aged 18 to 50 years seen in the rheumatology clinic. Four categories of clinical interventions were initiated with a goal to reduce barriers and improve effectiveness of counseling. Rheumatology providers were surveyed before and after implementing these interventions.</p><p><strong>Results: </strong>Seventy percent of all patients and 85% of patients who took teratogenic medications reported having ever received reproductive health counseling by a rheumatologist. Counseling rates were higher in younger women and those who took teratogenic medications. Women who had previously received counseling were less likely to be unsure whether they were safe to become pregnant and more likely to talk to their rheumatologist if they decided to become pregnant in the future. Patient-reported rates of counseling poorly agreed with medical chart documentation of counseling, except in women taking teratogenic medications. Most providers found the clinical interventions made it easier to provide counseling, and the number of referrals to Family Planning clinic increased by 625%.</p><p><strong>Conclusion: </strong>Reproductive health counseling for rheumatology patients of childbearing potential is essential. Ongoing efforts should focus on promoting consistent, high-quality counseling that translates into meaningful outcomes for patients.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":"1298-1303"},"PeriodicalIF":4.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13322379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146148947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply.","authors":"Lisa R Sammaritano, Anca Askanase, Bonnie L Bermas, Maria Dall'Era, Alí Duarte-García, Linda T Hiraki, Mary Beth F Son, Victoria P Werth, Reem A Mustafa","doi":"10.1002/acr.80152","DOIUrl":"https://doi.org/10.1002/acr.80152","url":null,"abstract":"","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148863543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilization of Rehabilitation Services Among People With Common Autoimmune Rheumatic Diseases: A Systematic Review.","authors":"Joel R Thompson, Keri Geinosky, Josh C Torrey, Astia Allenzara, Louise M Thoma","doi":"10.1002/acr.80002","DOIUrl":"10.1002/acr.80002","url":null,"abstract":"<p><strong>Objective: </strong>Rehabilitation services, including physical and occupational therapy, are frequently recommended in the management of many autoimmune rheumatic diseases (ARDs), yet utilization remains unclear. This systematic review aimed to evaluate how frequently people with common ARDs utilize rehabilitation services.</p><p><strong>Methods: </strong>We conducted a systematic review of studies published through December 2023 that reported rehabilitation utilization (percentage utilization and/or number of visits) among individuals with ARDs. PubMed and CINAHL were searched. Two reviewers independently screened studies, and data were extracted and summarized by disease, discipline, reporting period, and country.</p><p><strong>Results: </strong>Of 11,591 records identified, 113 studies met inclusion criteria, and 86 were included in the final analysis. These studies were published between 1991 and 2023, with data representing 22 countries. Rehabilitation utilization was most frequently reported for rheumatoid arthritis (n = 59), axial spondyloarthritis (n = 25), and systemic sclerosis (n = 20). Percentage utilization rates ranged from 0% to 100%, and annual visit counts ranged from 1 to 62.1, varying widely across and within disease types, reporting periods, and countries. Physical therapy was more commonly reported and utilized than occupational therapy. Utilization rates were generally higher in European countries compared to North America.</p><p><strong>Conclusion: </strong>There was heterogeneity across studies underscoring wide variability in the use of rehabilitation services. These findings highlight inconsistent integration of rehabilitation into rheumatology care across diseases and health systems. Future research should investigate current barriers and facilitators and inform the development of systematic, equitable, and disease-specific strategies to optimize access and delivery of rehabilitation for people with ARDs.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":"1277-1286"},"PeriodicalIF":4.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13511388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}